Wilson Yip

Senior Associate

I have nearly 20 years of experience in general corporate and commercial matters, takeovers and mergers, corporate finance, regulatory compliance and corporate governance matters. I act for Hong Kong listed companies, including state-owned enterprises and PRC issuers having dual listing in Hong Kong and Shanghai, advising them on transactions and other matters subject to compliance of Hong Kong Listing Rules and on-going compliance obligations under the Hong Kong Listing Rules.

With broad experience in compliance of Hong Kong Listing Rules and the relevant laws, my focus is on:

  • advising on structure of transactions and other matters subject to Hong Kong Listing Rules;
  • on-going compliance of Hong Kong Listing Rules.

Career Highlights

Mergers & Acquisitions

  • advised Golden Meditech Holdings Limited (a Hong Kong listed company) on its RMB5.764 billion disposal of all its shares in China Cord Blood Corporation, the first umbilical cord blood banking operation
  • advised Yuexiu Transport Infrastructure Limited (a company previously listed in Hong Kong which had been privatised) on its RMB5.8 billion acquisition of the controlling stake in a group of PRC companies which operates three expressways located in Hubei Province, China.

Capital Markets

  • advised Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, a Hong Kong and Shanghai dual-listed PRC State-owned company, on its placing of new A-Shares to a consortium of five investors to raise RMB10 billion for its expansion projects. The company simultaneously implemented an employee stock ownership scheme under the new regulations introduced by China’s Securities Regulatory Commission in June 2014. Guangzhou Baiyunshan Pharmaceutical is believed to be one of the first Hong Kong/Shanghai dual-listed companies to adopt and issue new shares for the benefit of such employee stock ownership scheme. This deal was awarded “Deal of the Year 2015” by China Business Law Journal.
  • advised China Sandi Holdings Limited (a Hong Kong listed company) on its HK$329.8 million rights issue and the application of a whitewash waiver from the Securities and Futures Commission of Hong Kong.
  • advised Golden Meditech Holdings Limited on its fund raising of approximately HK$570 million by an open offer. The deal involved dual filing of prospectus in Hong Kong and Taiwan where the company’s Taiwan Deposit Receipts were listed, and submissions to the Securities & Futures Commission of Hong Kong regarding Takeovers Code issues.